Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Baird Medical Investment Holdings (BDMDW) Work In Process (2023 - 2025)

Baird Medical Investment Holdings' quarterly Work In Process came in at $200045.0 in Q4 2025, down 13.16% year-on-year from $230355.0 in Q4 2024, and down 13.16% quarter-over-quarter from $230355.0 in Q4 2024.

Baird Medical Investment Holdings has reported Work In Process for 3 years, with the latest figure at $200045.0 in Q4 2025.

  • For the quarter ending Q4 2025, Work In Process fell 13.16% year-over-year to $200045.0; the trailing twelve-month figure through Dec 2025 stood at $200045.0 (down 13.16% YoY), and the FY2025 full-year result was $200045.0, down 13.16% from the prior year.
  • Work In Process for Q4 2025 stood at $200045.0, down from $230355.0 in the prior quarter.
  • The five-year high for Work In Process was $313352.0 in Q4 2023, with the low at $200045.0 in Q4 2025.
  • Average Work In Process over 3 years is $247917.3, with a median of $230355.0 recorded in 2024.
  • Year-over-year, Work In Process decreased 26.49% in 2024 and dropped 13.16% in 2025.
  • Tracing BDMDW's Work In Process over 3 years: stood at $313352.0 in 2023, then fell by 26.49% to $230355.0 in 2024, then slipped by 13.16% to $200045.0 in 2025.
  • The last three Work In Process figures came in at $200045.0 (Q4 2025), $230355.0 (Q4 2024), and $313352.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Baird Medical Investment Holdings - - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 200,045.00
Dec 31, 2024 230,355.00
Dec 31, 2023 313,352.00